News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Actelion Ltd. Swings to Profit, Key Drug Tracleer Disappoints
April 22, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, April 22 (Reuters) - Swiss biotech company Actelion Ltd swung to a first-quarter net profit of 48 million Swiss francs ($47.43 million), but results were hit by the weak dollar and sales of key drug Tracleer disappointed.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Earnings
No Trump Drug Pricing Plan for J&J—Yet
October 14, 2025
·
3 min read
·
Annalee Armstrong
Layoff Tracker
Latest Novo Cuts Affect Almost 250 Cell Therapy Employees
October 14, 2025
·
70 min read
·
BioSpace Editorial Staff
Series B
Kailera Banks Massive $600M Raise for Phase III Obesity Study
October 14, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Violations at Novo’s Indiana Plant ‘Unacceptable,’ FDA Says
October 14, 2025
·
2 min read
·
Tristan Manalac
